Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gloria Lee, MD, PhD
HUYABIO International, LLC.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
139 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sydney Adventist Hospital
Wahroonga, New South Wales, Australia
- University of the Sunshine Coast
Buderim, Queensland, Australia
- Icon Cancer Centre Wesley
South Brisbane, Queensland, Australia
- Ballarat Health Services
Ballarat, Victoria, Australia
- Goulburn Valley Health
Shepparton, Victoria, Australia
- Royal Brisband and Women'S Hospital
Brisbane, Australia
- Liverpool Hospital
Liverpool, Australia
- Affinity Clinical Research
Nedlands, Australia
- Tweed Hospital
Tweed Heads, Australia
- Calvary Mater Newcastle
Waratah, Australia
- Medical University of Graz Department of Dermatology and Venerology
Graz, Austria
- Univ.-Lkinik Für Dermatologie, Venerologie Und Allergologie
Innsbruck, Austria
- Az Klina
Brasschaat, Belgium
- Cliniques Universitaires
Brussels, Belgium
- Az Maria Middelares
Ghent, Belgium
- Jessa Ziekenhuis
Hasselt, Belgium
- Hospital de la Citadelle
Liège, Belgium
- Clinique Saint-Pierre
Ottignies, Belgium
- Ensino E Terapia de Inovação Clίnica Amo-Etica
Salvador, Estado de Bahia, Brazil
- Hospital Erasto Gaertner - Liga Paranaense de Combate Ao Câncer,
Curitiba, Paraná, Brazil
- Hospital Do Câncer de Londrina
Londrina, Paraná, Brazil
- Hospital São Vicente de Paulo
Centro, Rio Grande do Sul, Brazil
- Hospital Bruno Born
Lajeado, Rio Grande do Sul, Brazil
- Centro Gaúcho Integrado de Oncologia, Hematologia
Porto Alegre, Rio Grande do Sul, Brazil
- Hospital de Clίnίcas de Porto Alegre
Santa Cruz do Sul, Rio Grande do Sul, Brazil
- Oncosite-Centro de Pesquisa Clίnica Em Oncologia
São Cristóvão, Rio Grande do Sul, Brazil
- Hopital de Câncer de Barretos-Fundação Pio Xii
Barretos, São Paulo, Brazil
- Fundação Doutor Amaral Carvalho
Jaú, São Paulo, Brazil
- Cepho-Centro de Estudos E Pesquisas de Hematologia E Oncologia
Santo André, São Paulo, Brazil
- Fundação Faculdade Regional de Medicina de São José Do Rio Preto
São José do Rio Preto, São Paulo, Brazil
- Instituto Do Cancer Do Estado de São Paulo - "octavio Frias de Oliveira"-Icesp
São Paulo, São Paulo, Brazil
- Fakultni Nemocnice Olomoue
Olomouc, Czechia
- Fakultni Nemocnice Ostrava Kozni Oddeleni
Ostrava-Poruba, Czechia
- Fakultni Nemocnice Kralovske Vinohrady
Prague, Czechia
- Chu de Besançon - Hôpital Jean Minjoz
Besançon, France
- Hôpital Ambroise Paré
Boulogne-Billancourt, France
- Chu de Dijon, Service de Dermatologie
Dijon, France
- Chu Grenoble Alpes
La Tronche, France
- Chru Lille - Hôpital Claude Huriez, Clinique de Dermatologie
Lille, France
- Hôpital la Timone
Marseille, France
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Aug 2021
- Primary completion
- 31 Jul 2026
- Completion
- 31 Dec 2026
- Last update posted
- 24 Sept 2025
- Registered enrollment
- 450
- Registry id
- NCT04674683
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.